Company / Return on Assets (ROA)
Gain Therapeutics, Inc. Return on Assets (ROA) History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-183.7%
FY2024
5-year range
-183.7% / -9.2%
FY2021-FY2024
Trend
-94.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Assets (ROA) has declined for 3 consecutive years, from -9.2% in FY2021 to -183.7% in FY2024.
Based on SEC 10-K filings.
-183.7% in FY2024 with a 3-year CAGR of -174.5%.
Declined from -57.6% to -183.7% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -174.5pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- Gain Therapeutics, Inc.'s return on assets (roa) has declined for 3 consecutive years.
- In FY2024, return on assets (roa) decreased 94.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -183.7% | -94.3% |
| FY2023 | -94.5% | -64.0% |
| FY2022 | -57.6% | -527.9% |
| FY2021 | -9.2% | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026